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Acute ischemic stroke treatment,
part 2: Treatment
“Roles of capillary index score,
revascularization and time”
Firas Al-Ali1*, John J. Elias2 and Danielle E. Filipkowski2
1 Department of Neuro Interventional Surgery, Akron General Medical Center, Akron, OH, USA, 2 Department of Research,
Akron General Medical Center, Akron, OH, USA
Due to recent results from clinical intra-arterial treatment for acute ischemic stroke (IAT-
AIS) trials such as the interventional management of stroke III, IAT-AIS and the merit of
revascularization have been contested. Even though intra-arterial treatment (IAT) has been
shown to improve revascularization rates, a corresponding increase in good outcomes
has only recently been noted. Even though a significant percentage of patients achieve
good revascularization in a timely manner, results do not translate into good clinical
outcomes (GCOs). Based on a review of the literature, the authors suspect limited GCOs
following timely and successful revascularization are due to poor patient selection that led
to futile and possibly even harmful revascularization. The capillary index score (CIS) is a
simple angiography-based scale that can potentially be used to improve patient selection
to prevent revascularization being performed on patients who are unlikely to benefit from
treatment. The CIS characterizes presence of capillary blush related to collateral flow as
a marker of residual viable tissue, with absence of blush indicating the tissue is no longer
viable due to ischemia. By only selecting patients with a favorable CIS for IAT, the rate of
GCOs should consistently approach 80–90%. Current methods of patient selection are
primarily dependent on time from ischemia. Time from cerebral ischemia to irreversible
tissue damage seems to vary from patient to patient; so focusing on viable tissue based
on the CIS rather than relying on an artificial time window seems to be a more appropriate
approach to patient selection.
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Introduction
The interventional management of stroke (IMS) III trial (1) showed non-superiority of intra-
arterial (IA) revascularization combined with intra venous (IV) tissue plasminogen activator (tPA)
treatment over IV tPA alone, and the systemic thrombolysis for acute ischemic stroke (SYNTHESIS)
trial demonstrated similar lack of favorable clinical outcomes for IA versus IV tPA therapy (2).
This is despite the high revascularization rate in the IA arms in these trials. The role of intra-
arterial treatment for acute ischemic stroke (IAT-AIS) has been contested. Paradoxically, however,
the benefit of revascularization to clinical outcomes is convincingly attested to in prior literature. In a
recent meta-analysis of 998 patients with clinical follow-up at 3months, good clinical outcome was
found in 58% of revascularized patients as compared to 24.8% in non-revascularized patients (3).
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When revascularization occurred within the first 6 h, good clin-
ical outcomes (GCOs) were found in 50.9% of revascularized
patients as compared to 11.1% in non-revascularized patients.
Other authors reached similar conclusions. Even in the IMS III
trial, better revascularization using the modified thrombolysis in
cerebral infarction (mTICI) score led to better outcomes than
those for patients who achieved lesser revascularization (1). This
data were recently resolved with the publication of newer trials.
In MR CLEAN, EXTEND-IA, and ESCAPE, good recanalization
rates were achieved in 58.7, 86, and 72.4% of patients, respectively,
with accompanying GCO rates at 32.6, 71, and 53%, respectively
(4–6). While these results demonstrate IA superiority with higher
recanalization rates than with IVT, there are still a significant
number of patients who achieved good and timely revasculariza-
tion that did not also achieve GCOs. So if better revascularization
improves outcome and IA treatment has a better revascularization
rate than IV treatment, how can we explain the lack of GCOs in
some of these patients?
Revascularization and Outcome
Revascularization is defined as the restoration of anterograde
blood flow to the ischemic area through the recently occluded
artery. Currently, this is reported using the mTICI score, with
mTICI of 2b or 3 being considered successful revasculariza-
tion (7). The aim of revascularization is to produce clinical
improvement through restoring the cerebral blood flow (CBF)
level to greater than the critical threshold of 23ml/100 g/min
of viable brain tissue (8). This should translate into a per-
manent resolution of AIS symptoms by saving the ischemic
tissue before it progresses to irreversible damage. So if per-
fect revascularization is achieved (mTICI= 3) in a timely man-
ner, i.e., before ischemia becomes irreversible, clinical improve-
ment should be achieved for almost all patients, as well as
for the majority of patients with less effective revascularization
(mTICI= 2b). However, review of the literature reveals that only
around 50% of patients in whom we obtained timely recanal-
ization (mTICI 2b, 3) will achieve a good clinical outcome
(Table 1) (1, 2, 9–13). Attempting to solve the paradox regarding
why all technically successful revascularizations do not trans-
late into GCOs should help us improve our revascularization
strategy.
Revascularization Rate
Revascularization rate depends heavily on the mode of treatment
used (3). Spontaneous recanalization is estimated at 24% within
the first 24 h (3). By comparison, overall data suggest that IV
tPA results in recanalization in 46% of patients, as compared to
63% for IA thrombolysis, and 68% when the combined thera-
pies (IV+ IA) are utilized. Mechanical thrombectomy achieved
the highest recanalization rate at 84% (3). It is estimated that
revascularization is associated with a four to fivefold increase in
good clinical outcome rates. Since higher revascularization rates
correlate with better outcome in the literature and mechanical
thrombectomy has the highest revascularization rate, it is now the
preferred method for most operators.
TABLE 1 | Clinical outcomes across IAT-AIS trials.
Trial % mRS 0–2 (3months) Time to IAT (h) % TIMI 2, 3
PROACT II 42.3a 4.5b 58
IMS I 43 3.050.8b 56
IMS II 46 n/a 64
IMS III 40.8 3.5b 81d
SYNTHESIS 41.9 3:45c n/a
SWIFT 37 4.9b 83
TREVO 2 39.9 4.7c 90
MR CLEAN 32.6 4.3c 58.7d
EXTEND-IA 71 3.5c 86d
ESCAPE 53 3.1c 72.4d
aBarthel index 9 and 10.
bMean.
cMedian.
dTICI 2,3 for M1 occlusion.
Mechanical Thrombectomy
The original method of mechanical thrombectomy was micro-
wire and micro-catheter clot manipulation during IA tPA or pro-
Urokinase infusion. InAsia, balloon angioplasty is used frequently
as a mechanical method with an excellent recanalization rate of
80% (3). In the Western hemisphere, while balloon angioplasty is
used, the predominatemode ofmechanical recanalization is either
a stent retrieval or the Penumbra system.
Stent retrieval systems are designed to restore blood flow by
catching the thrombus through the stent struts. Flow cessation
is then induced in the internal carotid artery using a balloon-
mounted guiding catheter. At this time, the clot is removed by
dragging it through the guiding catheter while applying suction
on the guiding catheter to decrease the chance of a clot fragment
migrating downstream. There are two available stent retrieval
systems in the market today: the Trevo™ Pro Vu™(Stryker, Kala-
mazoo, MI, USA) and the Solitaire™(Covidian, CA, USA). Both
devices are constructed of Nitinol with a laser cut design that
can be delivered through a standard 0.021 or 0.027-inch (internal
diameter) microcatheter.
The Trevo™ ProVue™ consists of a flexible, tapered core wire
with a shaped section at the distal end. Radiopaque platinumwires
in the shaped section and a guide wire-like tip allow fluoroscopic
visualization. It is constructed of a straight cut tube that includes
a distal taper and wire. Its struts are constructed perpendicularly
to the clot in an attempt to engage the thrombus. The Solitaire™,
on the other hand, has a proprietary overlapping stent technology
called Parametric™ Design that provides multiple planes of clot
contact (Solitaire IFU). Both stents have demonstrated compa-
rable and excellent revascularization rates in prospective registry
studies. In a recent prospective study of 227 patients, the Solitaire™
system had excellent results of 71% mTICI 2b or 3 (14), while
the Trevo™ Pro Vu™ demonstrated 86% TICI 2 or 3 revascular-
ization in the Trevo versus Merci retrievers for a thrombectomy
revascularization (TREVO 2) randomized trial (13).
The Penumbra System™(Penumbra Inc., Fremont, CA, USA) is
an aspiration system that utilizes an entirely different mechanism
of mechanical clot retrieval. The device uses a suction mecha-
nism to retrieve the clot inside the catheter by lodging the tip
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of the catheter in the proximal end of the clot while simultane-
ously hooking its hub to a suction machine creating pure suction
( 29mmHg at sea level). In the initial pivotal study that included
125 patients, recanalization rates utilizing the Penumbra system
were 82% thrombolysis in myocardial infarction (TIMI) score of
2 or 3 (15), later confirmed by a second prospective trial with 87%
revascularization rates (TIMI 2 or 3) (16).
From Technically Successful to Clinically
Beneficial Revascularization
Technically successful revascularization does not always lead to
good, i.e., beneficial, clinical outcomes. Some technically success-
ful revascularizations are futile (not followed by clinical improve-
ment) while others are outright harmful (cause clinical deteriora-
tion). Several factors may contribute to these variations:
Patient Selection: The Capillary Index Score
In patients who already suffered a large area of irreversible
ischemic injury, reconstituting the anterograde blood flow will
not be beneficial, and can actually be harmful by increasing the
risk of vasogenic edema and/or hemorrhagic transformation, as
well as possible herniation. We believe one reason why good
revascularization does not always lead to good clinical outcome
is poor patient selection, i.e., treating patients with already irre-
versible ischemia. The capillary index score (CIS) is a simple
angiography-based scale for assessing viable tissue in the ischemic
territory. The CIS is comprised of a 4-point scale ranging from 0
(no angiographic capillary blush) to 3 (the whole ischemic area
exhibits capillary blush), with the presence of capillary blush pro-
posed as a marker of residual viable tissue, with absence implying
irreversible ischemia. Favorable CIS (fCIS) is defined as a score
of 2 or 3 and was found to be nearly a prerequisite for a good
clinical outcome (modified Rankin Scale, mRS, score of 2 or
lower at 90 days) (17), whereas a poor CIS (pCIS) is defined as a
score of 0 or 1. If the assumption that the presence of capillary
blush indicates viable tissue and its absence implies irreversible
ischemia is correct, then selecting only patients with fCIS for
treatment should significantly increase the percentage of patients
with GCOs following technically successful intervention. At the
same time, by not offering treatment to patients with pCIS, there
should be a significant decrease in the percentage of futile or
harmful revascularization, further increasing the percentage of
patients with GCOs. Indeed, in the Borgess Medical Center-acute
ischemic stroke registry (BMC-AIS), 83% of patients with fCIS
who achieved TIMI 3 revascularization had good clinical outcome
(mRS 0–2) (17). In a subgroup analysis of IMS I, II trials using the
CIS and TIMI scores, 100% of the five patients with a fCIS and
good revascularization (mTICI 2b, 3) had good clinical outcome
(18). To our knowledge, this represents the highest percentage of
GCOs following good revascularization that has been reported,
suggesting that the CIS is the most accurate tool, to date, for
patient selection in AIS treatment.
Territory Selection: Complete Versus Optimal
Revascularization
The current understanding of revascularization is that clinical
benefits of revascularization increase with its extent (1, 19). In the
TABLE 2 | IMS III results – clinical outcome and revascularization status (1).
mTICI mRS 0–2 at 3months (%)
0 12.7
1 27.6
2a 34.3
2b 47.9
3 71.4
IMS I and II trials, better revascularization led to better outcome –
46 versus 58% for TICI 2 or 3 versus mTICI 2b or 3, respectively
(19). Even in the IMS III, despite its overall results, better revas-
cularization in the IA arm translated into better clinical outcomes
(Table 2) (1). However, if we accept the assumption that capillary
blush indicates viable tissue, we should not be guided solely by the
desire to obtain as complete revascularization as possible. Rather,
the aim of revascularization should be to reconstitute anterograde
flow solely to the territory with persistent capillary blush through
the pial collaterals (viable tissue), while resisting the temptation
to establish an anterograde flow to the territory void of capillary
blush (non-viable tissue). In other words, and counter-intuitively,
for a technically successful revascularization to be clinically bene-
ficial, it does not necessarily need to be as complete as possible, but
rather it should aim to restore an anterograde flow only to the area
with persistent capillary blush. Following revascularization, one
should not see capillary blush that did not exist prior to intervention.
Complication Rates
All forms of intervention, no matter how simple, carry the risk
of complications. IAT-AIS is a very complex and technically
demanding procedure, and at times it requires clinicians to cross
occluded vessels blindly without any road mapping or prior
knowledge of the patient’s anatomy. Furthermore, most of these
patients are advanced in age and have difficult vessels to navigate.
Complications related strictly to the revascularization attempts
certainly exist; some of them are obviously device-specific. Unfor-
tunately, information is lacking about the actual complication
rate during IAT-AIS. Since these patients are already symptomatic
prior to intervention, it is difficult to reliably determine howmuch
an unsuccessful intervention contributed to overall patient symp-
toms or functional outcome impairment during their hospital stay.
The only prospectively available data on complication during the
revascularization procedure comes from the Penumbra™ aspira-
tion system with a 13% total complication rate in the Pivotal
study (3% deemed serious) and 6% in the post study (15, 16).
Complication rates of 3%with the Solitaire™ systemwere reported
in a review article involving 13 prior papers comprised of 262
patients (20). This included five subarachnoid hemorrhages, two
self-detachments of stent, one entanglement of stent, and one in-
stent thrombosis. Currently, no published data regarding Trevo
complications are available, but the rates are likely similar to the
other devices. We can thus conclude that mechanical interven-
tion devices carry approximately 5% complication rate, which
would ultimately negatively affect the overall odds ratio of better
outcomes following IAT-AIS. Decreasing the complication rate is
mandatory if wewant to increase the percentage of treated patients
with GCOs.
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The Different Forms of Revascularization
There are three forms of technically successful revascularizations:
beneficial, futile, and harmful. We believe that beneficial revas-
cularization, i.e., revascularization followed by clinical improve-
ment, occurs when revascularization is completed only on the
areas with persistent capillary blush via collaterals (prior to inter-
vention). The role of revascularization here is simply to reverse
the retrograde flow supplying the ischemic area to anterograde
flow and by doing so raise the CBF above the critical threshold
of ischemia. Therefore, technically successful and beneficial, revas-
cularization can be defined as: reversing the flow to an ischemic
area with persistent capillary blush, from retrograde to antegrade
without complications.
The other forms of revascularization are futile (no clinical
improvement) and harmful (followed by clinical deterioration).
These occur when revascularization is performed on an area void
of capillary blush prior to intervention, i.e., to non-viable cerebral
tissue, or due to a complication during a revascularization attempt.
In order to enhance the benefit of intra-arterial treatment (IAT),
we need first to redefine our revascularization strategy by mini-
mizing the performance of futile and harmful revascularization.
To achieve this goal, we propose the following strategy: select
patients correctly with fCIS and obtain as complete and timely
revascularization as safely possible, solely to the viable tissue, i.e.,
the areas with persistent capillary blush.
Intra-Arterial Versus Intra-Venous
Treatment
The recent results of the IMS III (1) and SYNTHESIS (2) trials are
most likely due to poor patient selection and high percentages of
futileorharmful revascularizations.Byadapting theCIS forpatient
selection and a more nuanced strategy for revascularization, we
should consistently approach the 80–90% clinical improvement
rate in the treated subgroup, as we saw in the BMC-AIS registry
and the subgroup analysis of IMS I, II. This percentage cannot be
reached using IV treatment alone due to the lower revasculariza-
tion rate associated with IV treatment and its inability to assess the
collateral supply prior to treatment, which will invariably lead to
a higher percentage of futile and harmful recanalization.
Time to Revascularization and Outcome
The Relationship of Time to Revascularization
and Outcome: Is it Linear?
Selection Bias
A linear relationship between time from ictus to revascularization
and outcome is suggested from few previous trials (21–25). How-
ever, it is important to note that a selection bias exists in these
trials since a significant portion of patients are excluded either
due to the presence of imaging evidence of counter-indication for
AIS treatment (signs of irreversible brain damage) or due to an
artificial time window. Hence, even if the relationship between
time from ictus to recanalization and outcome is perfectly linear
in this subgroup of patients, we cannot deduce from it the overall
relationship between time and outcome for all patients presenting
with AIS.
Literature Review
The suggested linear relationship between time and outcome is
not supported by empirical data when we reviewed the recent
IAT-AIS trials. Reviewing themost recent large, prospective trials,
the IMS III (1) and SYNTHESIS (2), as well as the two most
recent device studies, solitaire with the intention for thrombec-
tomy (SWIFT) and Trevo 2, reveal an almost identical clinical
improvement rate despite significant differences in time from ictus
to treatment across these studies (Table 1) (1, 3, 12, 13). The
SWIFT and the Trevo 2 trials had similar results with a percentage
of good clinical outcome (mRS 2) at 37 and 40%, respectively;
the mean time from ictus to treatment was 4.9 h in the SWIFT
study, and the median for Trevo 2 was 4.7 h (12, 13). Both trials
included patients up to 8 h from ictus (12, 13). Meanwhile, in the
IMS III trial, the IV treatment had to start within 3 h from ictus,
while the IA treatment had to start within 5 h and finish by 7 h post
ictus; yet, the study operators reported almost identical results
with 40.8%mRS 0–2 at 3months (1). In addition, the SYNTHESIS
trial had a shorter time from ictus to treatment (median of 3:45 h;
range 3:14–4:20) with a similar percentage of mRS 0–2 at 42% of
mRS 0–2 (2). If the relationship between outcome and time from
ictus to revascularization was linear, we would expect a higher
percentage of mRS improvement in the SYNTHESIS trial than the
IMS III trial, and a higher percentage in the IMS III trial than the
SWIFT and Trevo 2 trials; yet, all reported an almost identical
good clinical outcome rate. Furthermore, there are numerous
series reporting almost identical percentages of GCOs (around
40%) on patients treated after the traditional 6-, even up to 8-h
window (25, 26). It is difficult to reconcile these observations with
a linear relationship between time from ictus to revascularization
and outcome.
The Collateral Supply and the Logarithmic
Curve of Time to Outcome
Crowell et al. have shown that following the arterial occlusion
there is a sudden and abrupt drop in CBF (27). However, ischemia
is never total and residual flow to the ischemic areas invari-
ably persists through pial collaterals. Residual CBF (rCBF) will
remain stable until revascularization occurs or cell death ensues.
Studies have shown that time until ischemia becomes irreversible
is heavily dependent on the rCBF, which varies depending on
the collaterals present (8, 27). In other words, following cerebral
ischemia, different patients will have varying amounts of time
before cell injury becomes irreversible (Figure 1).
As we argued in a previous paper (18), whenwe consider a large
cohort of patients with acute ischemic stroke we can grossly divide
them into three groups depending on their rCBF. The first group
will have such a low rCBF value that they will experience irre-
versible ischemiawithin an hour or two of ictus. For these patients,
time to revascularization and its degree are irrelevant since the
cerebral tissue will be irreversibly damaged by the time the patient
arrives at the hospital. They are either not enrolled in studies due
to evidence of ischemia on a computed tomography (CT) scan and
other imaging modality, or do not improve following treatment
despite timely and good revascularization (futile revasculariza-
tion). We propose that approximately half of all AIS patients do
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FIGURE 1 | Depth of ischemia and time to irreversible cerebral
damage: time to irreversible cerebral damage depends on the depth
of ischemia, which depends on the collateral supply. Since different
patients have different collaterals, the depth of ischemia will vary among
patients, as will the time available for therapy to salvage the tissue (8).
Adapted with permission from Jones et al., (8). Permission has been obtained
from the American Association of Neurological Surgeons.
not have sufficient collaterals to sustain ischemia until revascu-
larization, no matter how fast it can be achieved, called “the 50%
barrier.” A second group of patients will present with intermediate
rCBF thatwill follow an approximately linear relationship between
time to revascularization and outcome (a subtle gradual decrease).
These patients are most often included in trials and registries.
Finally, a third group has a higher rCBF than the others, but still
below the critical symptomatic level of 23ml/100 g/min (8). This
group will exhibit a more asymptotic, flat curve relating time to
revascularization and outcome, but they are usually excluded from
studies when presenting outside the artificial time window. If we
assemble these three groups as a whole, the relationship between
time from ictus to revascularization and outcome will resemble a
logarithmic function (Figure 2). In other words, if the patient has
poor pial collaterals, no time will be fast enough. On the other
hand, if pial collaterals are present and robust, we have longer
time to revascularize the patient [not measured in minutes, but
in hours (28)]. Simply put, if the patient has good collaterals they
have time; if a patient has no collaterals they have no time.
Patient Selection
The obvious implication of this logarithmic understanding of the
time curve is the abandonment of any artificial time window to
treatment since each patient will have his or her own time until
irreversible ischemia occurs. Relying heavily on an arbitrary time
window will significantly decrease the accuracy of patient selec-
tion inAIS treatment, either by including patientswith irreversible
ischemia just because they presented within the traditional time
window and thereby leading to futile revascularization, or by
denying treatment to patients who may still have viable tissue
simply because they presented outside the traditional window.We
irreversible ischemia
linear
relaonship
50%
barrier
cannot be
treated 
fast enough
reversible ischemia
Logarithmic Time Curve to Irreversible Ischemia
y = 6.3ln(x) + 3.1
treatable beyond
standard window
FIGURE 2 | Logarithmic time curve: the infarction threshold
distinguishing between reversible and irreversible ischemia as a
function of rCBF and time from ictus. The vertical lines are an
approximation and have not yet been validated (18). Reproduced with
permission from Al-Ali et al. (18). Permission has been provided by Wolters
Kluwer Health, Inc.
propose a different patient selection algorithm, based more on
objective signs of cerebral ischemia as opposed to an arbitrary time
window.
Proposed Patient Selection Algorithm
We recognize that the merit of the CIS still needs to be proven
in a multicenter prospective study; however, we believe the CIS
hypothesis will be proven true due to its ability to explain the
results of the different ischemic stroke trials.
Since most patients will improve to a variable degree with time
and physical therapy, we believe that IAT should be offered to
patients suffering from a large stroke (NIHSS >8), with the only
exception being aphasia (Figure 3). Of those patients who are
Clinically Eligible, a non-enhanced head CT is obtained followed
by CTA. These non-invasive tests can first rule out stroke mim-
ics and identify patients with already visible signs of structural
changes due to large irreversible ischemia (i.e., hypodensity in
>1/3 MCA territory on head CT). If no such findings are identi-
fied, CTAwill help confirm the vascular occlusion and its location.
Patients with no counter-indication to treatment and proven large
vessel occlusion are offered IAT, CT Eligible. For these patients,
a full DCA is performed to obtain the CIS. Only patients who
demonstrate fCIS should be offered IAT since revascularization
on patients with pCISwill be futile and possibly harmful,CIS Eligi-
ble. If these steps are taken, we predict a significant increase in the
percentage of treated patients with GCOs by virtue of significantly
decreasing the percentage of futile and harmful revascularization.
It is important to note that time from ictus to presentation is
not included in this proposed algorithm. Since we believe that as
long the patients advance successfully from clinical, to CT, to CIS
eligibility, they are good candidate for intervention, regardless of
time from ictus to presentation.
Conclusion
Revascularization is the best hope forAIS patients. It should aim to
reverse the flow to an ischemic area with persistent capillary blush
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No IA Treatment
fCIS (2, 3)
Treat
Clinically Eligible
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CIS Eligible
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IAT-AIS
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Abnormal CT:
-Bleed
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head CT
LVO: Large vascular 
occlusion
FIGURE 3 | Proposed patient selection algorithm for AIS.
from retrograde to anterograde without complications. Time from
cerebral ischemia to irreversible damage varies from patient to
patient and depends on their pial collaterals. In other words, the
importance of time is secondary to the presence of collaterals. We
believe that the relationship between time from ictus to revascu-
larization and outcome is not linear, but logarithmic. Every patient
has his/her own time before irreversible ischemia is reached, so it
is critical to dispose of the artificial time window.
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